• Explore /
  • Poster
  • / A single-arm, open-label, phase I study of CPI-613 (Devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic adenocarcinoma.

A single-arm, open-label, phase I study of CPI-613 (Devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic adenocarcinoma.

Abstract Poster

Authors

null

Angela Tatiana Alistar

Atlantic Health System, Morristown, NJ

Angela Tatiana Alistar , Bonny Morris , Lawrence Harrison , Kai Bickenbach , Lee Starker , Nancy Ginder , Laura McIlwain , Sanjeev Luther , Timothy S. Pardee , Justin Alpert

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT03435289.

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4635)

DOI

10.1200/JCO.2020.38.15_suppl.4635

Abstract #

4635

Poster Bd #

243

Abstract Disclosures

Similar Posters

First Author: Angela Tatiana Alistar

First Author: Jaime Feliu Batlle

First Author: Mitesh J. Borad

First Author: Dong-Sheng Zhang